Yet, recent clinical trials have shown that SGLT2 inhibitors significantly decrease the risk of kidney injury in both diabetic and nondiabetic patients with CKD on top of RAS inhibitors (Zelniker et al., 2019; Cherney et al., 2020). The gene discussed is SLC5A2; the disease is chronic kidney disease.